Pharmacological Interventions for Neurological Manifestations of Ataxia-Telangiectasia: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
Muhammad Junaid Iqbal, Muteeba Azhar, Amina Hassan et al.
✦ AI-curated · Sources linked
In 30 seconds
This updated systematic review and meta-analysis examined randomized trials of pharmacological treatments for neurological manifestations of ataxia-telangiectasia in children and adults. Six trials evaluated betamethasone, N-acetyl-L-leucine/levacetylleucine, erythrocyte-encapsulated dexamethasone sodium phosphate (eDSP), or triheptanoin. In the two crossover trials contributing to the SARA meta-analysis, the pooled effect was not significant (MD -0.90, 95% CI -3.20 to 1.40; p = 0.443; I²=75.8%). A pooled secondary full-ICARS analysis favored eDSP, although neither eDSP trial met its prespecified primary neurological endpoint.
Key findings
- Across two crossover trials, pooled SARA treatment effect was MD -0.90 (95% CI -3.20 to 1.40; p = 0.443; I²=75.8%), not statistically significant.
- The pooled secondary full-ICARS estimate favored eDSP (MD -4.03, 95% CI -6.78 to -1.29), but neither trial met its prespecified primary neurological endpoint.
- For eDSP, pooled risk ratios were 1.05 (0.94 to 1.17) for any treatment-emergent adverse event and 0.94 (0.40 to 2.22) for serious adverse events.
- Betamethasone and triheptanoin were each represented by one randomized trial.
Why it matters
The review highlights uncertainty in the randomized evidence for improving neurological function in A-T. A favorable pooled secondary eDSP outcome should be interpreted alongside the unsuccessful primary endpoints, while the SARA estimate was not significant and showed substantial heterogeneity. These distinctions help clinicians assess the strength and consistency of efficacy and safety evidence without treating secondary pooled results as definitive.
What to keep in mind
The SARA meta-analysis included only two crossover trials and showed substantial heterogeneity (I²=75.8%). Betamethasone and triheptanoin were each evaluated in only one RCT; the review also identifies a need for harmonized, feasible neurological outcome measures.